Part-I- Balance Sheet
(All amounts in Indian Rupees unless otherwise stated)

		As at 31.0	3.2023	As at 31.0	3.2022
PARTICULARS	Note	Unaud		Unaud	ited
		INR	MYR	INR	MYR
ASSETS					
Non-Current Assets					
a) Property, Plant and Equipment		1941	241	22	(2)
b) Financial Assets					
i)Others			;=:	::e:	*
		3	-	3	ī
Current Assets					
a) Financial Assets					
i)Cash and Cash Equivalents	1	25,705	1,385	24,839	1,385
ii)Trade Receivable		81,371,990	4,382,991	12	-
b) Other Current Assets	2	9,662,543	520,460	83,717,587	4,666,584
		91,060,239	4,904,836	83,742,426	4,667,969
TOTAL		91,060,239	4,904,836	83,742,426	4,667,969
EQUITY AND LIABILITIES					
Equity					
a) Equity Share capital	3	464,135	25,000	448,495	25,000
b) Other Equity	4	(17,635,283)	(949,901)	(7,519,216)	(419,136)
		(17,171,148)	(924,901)	(7,070,721)	(394,136)
LIABILITIES					
Non-Current liabilities			The state of the s		
a) Financial Liabilities					
i) Borrowings	5	92,698,425	4,993,075	84,655,763	4,718,880
ii) Other Financial Liabilities	6	14,328,995	771,812	5,657,760	315,375
Current liabilities					
a) Financial Liabilities					
i) Other Financial Liabilities	7	1,203,966	64,850	499,623	27,850
		108,231,387	5,829,736	90,813,147	5,062,105
TOTAL		91,060,239	4,904,836	83,742,426	4,667,969

For and on behalf of the board of Directors of Indo Biotech SDN. BHD

Ramakant Innani

Director

Part - II - Statement of Profit and Loss

(All amounts in Indian Rupees unless otherwise stated)

Particulars	Note _	For the peri 31.03.2		For the peri 31.03.2	
i ai dedidi 5	Note	Unaudited		Unaud	ited
		INR	MYR	INR	MYR
Revenue Revenue from operations		÷	-	-	æ
Revenue from Operations Other income		778,005	42,936	-	-
Total Revenue		778,005	42,936	-	-
Expenses a) Employee benefits expense b) Finance costs c) Depreciation and amortisation expense d) Other expenses	8 9	326,162 7,966,637 - 2,102,713	18,000 439,657 116,043	360,171 4,688,430 729,094	20,250 263,599 * 40,992
Total Expenses		10,395,511	573,701	5,777,695	324,841
Profit / (Loss) before exceptional items and tax Exceptional items		(9,617,506)	(530,765)	(5,777,695)	(324,841)
Profit / (Loss) before tax		(9,617,506)	(530,765)	(5,777,695)	(324,841)
Tax expense a.Current tax b.Deferred tax (Net)					
		5		<u> </u>	35
Profit / (Loss) for the year Other comprehensive Income		(9,617,506)	(530,765)	(5,777,695)	(324,841)
Total Comprehensive Income Earning per equity share of face value of MR 1 (for continuing operations)		(9,617,506)	(530,765)	(5,777,695)	(324,841)
Basic Diluted		(96,175) (96,175)	(5,308) (5,308)	(57,777) (57,777)	(3,248) (3,248)
Weighted Average No of shares used in computing earnings per share Basic Diluted		100 100	100 100	100 100	100 100

For and on behalf of the board of Directors of Indo Biotech SDN. BHD

Ramakant Innani

Director '

(All amount are in Indian Rupees unless otherwise stated)

		equiva	

Particulars	As at 31.03	As at 31.03.2023		3.2022
	INR	MYR	INR	MYR
a) Balance with banks				
In Current Accounts	25,705	1,385	24,839	1,385
TOTAL	25,705	1,385	24,839	1,385

2 Other Current Assets

Outer Current Assets					
Particulars	As at 31.03	3.2023	As at 31.03.2022		
	INR	MYR	INR	MYR	
Unsesured (Considering Good)					
Other Receivables	9,662,543	520,460	83,717,587	4,666,584	
	9,662,543	520,460	83,717,587	4,666,584	
Doubtful	U#)	- E			
	9,662,543	520,460	83,717,587	4,666,584	
Less: Provision for doubtful advances	174)				
TOTAL	9,662,543	520,460	83,717,587	4,666,584	

3 Equity Share Capital

Particulars	As at 31.03.2023		As at 31.03.2022	
	INR	MYR	INR	MYR
Issued,Subscribed and fully Paid up 25000 Common Shares, RM 1/- each par value	464,135	25,000	448,495	25,000
TOTAL	464,135	25,000	448,495	25,000

4 Other Equity

Particulars	As at 31.0	03.2023	As at 31.03.2022	
r ai uculai s	INR	MYR	INR	MYR
	(7,461,646)	(419,136)	(1,683,951)	(94,295)
Balance at the beginning of the Reporting period				
Add: Total Comprehensive Income for the Year	(9,617,506)	(530,765)	(5,777,695)	(324,841)
	(17,079,152)	(949,901)	(7,461,646)	(419,136)
Foreign Currency Transalation Reserve	(556,131)		(57,570)	5
Balance at the end of the Reporting period	(17,635,283)	(949,901)	(7,519,216)	(419,136)

5 Long-term borrowings

Particulars	As at 31.	As at 31.03.2023		3.2022
	INR	MYR	INR	MYR
Unsecured Loan - From Shilpa Medicare Limited	92,698,425	4,993,075	84,655,763	4,718,880
TOTAL	92,698,425	4,993,075	84,655,763	4,718,880

(All amount are in Indian Rupees unless otherwise stated)

Other Financial Liabilities

Particulars	As at 31.0	03.2023	As at 31.03.2022	
	INR	MYR	INR	MYR
Interest accrued but not due on Borrowings	14,328,995	771,812	5,657,760	315,375
TOTAL	14,328,995	771,812	5,657,760	315,375

7 Other Current Liabilities

Particulars	As at 31.03.2023		As at 31.03.2022	
rai tiçulai s	INR	MYR	INR	MYR
Accounts Payable	1,203,966	64,850	499,623	27,850
TOTAL	1,203,966	64,850	499,623	27,850

8 Employee Benefits Expense

Particulars	For the peri 31.03.2	For the period ended 31.03.2022		
	INR	MYR	INR	MYR
Salaries & Wages	326,162	18,000	360,171	20,250
TOTAL	326,162	18,000	360,171	20,250

9 Finance Cost

Particulars	For the period ended 31.03.2023		For the period ended 31.03.2022	
	INR	MYR	INR	MYR
Interest on Loan from Shilpa Medicare Limited	7,966,637	439,657	4,688,430	263,599
TOTAL	7,966,637	439,657	4,688,430	263,599

10 Other Expenses

Particulars	For the period ended 31.03.2023		For the period ended 31.03.2022	
	INR	MYR	INR	MYR
Rent Expense	108,721	6,000	253,454	14,250
Travel Expenses	196	*	4,447	250
Exchange loss /(gain) net	1,758,431	97,043	9	9
Other Expenses	235,561	13,000	470,446	26,450
TOTAL	2,102,713	116,043	729,094	40,992